Abstract
We have no effective screening tools for ovarian cancer, in contrast to many other cancers. Thus, ovarian cancer usually is diagnosed after it has already progressed to stage III or IV. Despite aggressive measures, such as cytoreductive surgery and intravenous platinum-based chemotherapy, survival at 5 years among women with ovarian cancer is dismal. In the absence of a dedicated assay to quantify the incidence and rate of distant metastases, identification of factors that predict poor prognosis is of paramount importance. To investigate prognostic factors for advanced-stage …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
